Sunday 18 October 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMR
Alamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024. Insiders bought in the last twelve months.
25.28
2.14
−7.80%
Follow ALMR
| Dec '25 | Dec '24 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(0.86) | 0.92 |
P/FCF ratio |
0.00 | 0.00 |
Beneish M-Score |
(0.82) | — |
P/Operating CF |
(13.26) | (13.26) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(2.83) | (2.83) |
EV/FCF |
(2.64) | (2.64) |
Quick Ratio |
1.80 | 5.20 |
Current Ratio |
3.99 | 6.43 |
Net Debt/EBITDA |
0.74 | 1.65 |
Debt/Assets |
7.01% | 0.00% |
Debt/Equity |
0.13 | 0.00 |
Asset Turnover |
0.51 | 0.00 |
Operating CF/Net income |
1.80 | 1.19 |
Capex/Depreciation |
(1.37) | (2.13) |
Interest Coverage |
(78.14) | (23.85) |
| 20.40% | 0.00% | |
| (20.60%) | 0.00% | |
ROIC |
(35.06%) | (141.04%) |
Return on Tangible Assets |
(36.60%) | (47.39%) |
Average Days of Receivables |
62.72 | 96.51 |
Research and Development Expense of Revenue |
50.49% | 156.05% |
Selling, General and Administrative Expense of Revenue |
47.93% | 75.34% |
Intangible Assets out of Total Assets |
0.01 | 0.01 |
Share Based Compensation of Revenue |
3.87% | 3.47% |
Graham Net Nets |
0.04 | 0.04 |
Graham Number |
0.00 | 0.00 |
Earnings Yield |
(12.02%) | (12.02%) |
Free Cash Flow Yield |
(39.37%) | (39.37%) |
Revenue per Share |
6.43 | 2.39 |
Operating CF per Share |
(4.64) | (5.25) |
Capex per Share |
(0.47) | (0.28) |
Free Cash Flow per Share |
(5.11) | (5.53) |
Cash per Share |
2.60 | 7.57 |
Shareholders Equity per Share |
6.59 | 9.65 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
6.59 | 9.65 |
Free Cash Flow |
(58.98) | (58.16) |
Working Capital |
70.98 | 90.11 |
Capital Expenditures |
(5.37) | (2.95) |
Net Current Asset Value |
30.76 | 58.77 |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.07 | 0.12 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.37 | 0.18 |
Cash ROIC |
(50.91%) | (32.10%) |
Accounts Receivable Turnover |
7.65 | 0.00 |
Accounts Payable Turnover |
5.39 | 0.00 |
Inventory Turnover |
1.23 | 0.00 |
Average Days of Payables |
65.93 | 136.57 |
Days of Inventory on Hand |
432.10 | 318.05 |
Average Receivables |
9.70 | — |
Average Payables |
6.03 | — |
Average Inventory |
26.45 | — |
Average Assets |
144.75 | — |
Average Common Equity |
(146.18) | — |
Columns are period end dates